2. Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and metaanalysis. JAMA Oncol. 2019;5(7):1008-1019. 3. Zheng X,Tao G, Sun S, et al. Adverse events of different PD-1 inhibitors in lung can...
[7] Yucai Wang, Shouhao Zhou, Fang Yang, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-...
2. Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and metaanalysis. JAMA Oncol. 2019;5(7):1008-1019. 3. Zheng X,Tao ...
中国帕金森病注册登记研究(The Chinese Parkinson's Disease Registry, CPDR)是一项由中南大学湘雅医院发起的、多中心的、全国性的PD队列研究(在Clinical Trials网站登记注册(NCT03887663))。CPDR将通过互联网为授权人员提供一个用户友好的、加密的注册平台。CPDR的登记内容包括:人口统计学特征、临床特征、环境因素、家族史...
表3 聚合胶束相关药物临床试验(clinicaltrials.gov)[15] 胶束在口服药物中的应用 据报道,塞来昔布口服给药系统使用的是由Soluplus®(聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物)和Kolliphor®HS-15(聚乙二醇(15)-羟基硬脂酸酯)聚合物形成的胶束。研究发现,与上市配方相比,胶束可提高药物在大鼠体内的生物利用...
In this review, we systematically summarized the pathogenesis, especially the molecular mechanisms of PD, the classical research models, clinical diagnostic criteria, and the reported drug therapy strategies, as well as the newly reported drug candidates in clinical trials. We also shed light on the...
Parkinson’s disease clinical trials impacted by Covid-19 pandemic. Retrieved from clinicaltrialsarena.com . 4.Chang, Bowen, et al. "Bilateral globus pallidus interna combined with subthalamic nucleus variable frequency deep brain stimulation in the treatment of young-onset Parkinson’s disease with ...
目前,Clinical Trials有117项PD-1有众多非小细胞肺癌联合用药处于临床研究阶段,其中处于III期临床的项目包括Incyte公司IDO抑制剂和Pembrolizumab联用、默沙东Pembrolizumab和百时美施贵宝Ipilimumab(Yervoy,抗CTLA-4单抗)联用;处于II期临床的项目包括百时美施贵宝的Nivolumab和Ipilimumab联用、Xcovery/贝达药业的恩沙替尼和...
ORIENT-16研究是一项比较信迪利单抗或安慰剂,联合化疗(奥沙利铂+卡培他滨)一线治疗不可切除的局部晚期、复发性或转移性胃及胃食管交界处腺癌的有效性和安全性的随机、双盲、多中心、III期研究(ClinicalTrials.gov, NCT03745170)。主要研究终点为总体人群和PD-L1阳性人群(CPS>5)的总生存期(OS)1。
参考资料: 1. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat Rev Drug Discov. 2021 Mar;20(3):168-169. 2. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021 Mar 13;397(10278):1010-1022....